Knight Therapeutics Inc.
GUD.TO
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 69.83% | -699.19% | -80.15% | 12,209.47% | 104.39% |
| Total Depreciation and Amortization | 47.05% | 8.69% | -13.37% | -5.09% | 2.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -1.84% | 462.88% | 112.63% | -524.03% | 767.35% |
| Change in Net Operating Assets | -188.07% | 216.87% | 7.90% | -8.21% | 7.58% |
| Cash from Operations | -49.59% | 472.40% | 143.68% | -71.47% | 563.35% |
| Capital Expenditure | 33.56% | -72.41% | 35.03% | -45.88% | 45.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -70.73% | -- | -- |
| Cash Acquisitions | 97.00% | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -64.42% | -80.16% | 71.10% | 51.53% | -4.01% |
| Cash from Investing | 98.61% | -427.06% | 73.61% | 52.56% | -1.60% |
| Total Debt Issued | -- | 5,947.21% | 233.15% | -66.85% | 119.28% |
| Total Debt Repaid | 91.03% | -1,963.55% | 66.00% | -162.35% | 61.63% |
| Issuance of Common Stock | -65.29% | 218.42% | -18.57% | -68.75% | 31.76% |
| Repurchase of Common Stock | -- | 99.82% | 35.05% | -108.16% | -99.19% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 66.48% | -437.43% | 80.53% | -480.91% | 84.73% |
| Cash from Financing | -111.68% | 1,221.65% | 70.15% | -280.96% | 65.33% |
| Foreign Exchange rate Adjustments | 129.63% | -547.73% | -57.54% | 541.87% | 124.98% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 111.88% | -211.14% | 392.20% | -52.21% | 740.52% |